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Objective Preclinical evidence indicates that rapid changes in levels of allopregnanolone, the
predominant metabolite of progesterone, confer dramatic behavioral changes and may trigger
postpartum depression (PPD) in some women. Considering the pathophysiology of PPD (i.e., trig-
gered by reproductive steroids), the need for fast‐acting, efficacious treatments and the negative
consequences of untreated PPD, there is an increasing focus on developing PPD therapies.
Brexanolone (USAN; formerly SAGE‐547 Injection), a proprietary injectable allopregnanolone for-
mulation, was evaluated as a treatment for severe PPD in a proof‐of‐concept, open‐label study.
Methods Four women with severe PPD, defined as a baseline 17‐item Hamilton Rating Scale
for Depression (HAMD) score of ≥20, received brexanolone, titrated to a dose reflecting third‐
trimester allopregnanolone levels. After a 36‐hour maintenance infusion, tapering occurred over
12 hours. Primary outcomes were measures of safety. Secondary outcomes were assessments of
efficacy, including HAMD.
Results All enrolled patients completed the study. Fourteen adverse events were reported, of
which none was severe. Starting at the first measure after infusion initiation and continuing
through Hour 84, mean HAMD total scores were reduced to levels consistent with remission
of symptoms. All other efficacy assessments showed similar improvements.
Conclusions Brexanolone was well tolerated and demonstrated activity in severe PPD.
Larger, double‐blind trials are needed for further evaluation.
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Postpartum depression (PPD) is common in the perinatal period and
remains underdiagnosed and often untreated (Earls, 2010). Major or
minor depression is reported by up to 19.2% of mothers in the first
three postpartum months (Gavin et al., 2005), and PPD can lead to
significant morbidity and mortality for mother and infant (Beck,
1995; Fihrer, Mcmahon, & Taylor, 2009; Howard, Flach, Mehay, Sharp,
& Tylee, 2011; O'connor, Monk, & Burke, 2016). Hormonal changes
during pregnancy and postpartum are thought to play a role in thethe Creative Commons Attribution
d, the use is non‐commercial and
Clinical and Experimental published
waetiology of PPD (Bloch et al., 2000; Schiller, Meltzer‐Brody, &
Rubinow, 2015). The clinical presentation of PPD has distinguishing
characteristics in comparison to depression outside of the perinatal
period (Bernstein et al., 2008; Hendrick, Altshuler, Strouse, & Grosser,
2000). Symptoms of severe anxiety and rumination can manifest as the
primary clinical concern and significantly impact functioning
(Abramowitz et al., 2010; Bernstein et al., 2008).
Levels of allopregnanolone, the major metabolite of progester-
one, increase commensurate with the rise in progesterone during
pregnancy, with highest physiologic levels in the third trimester (Luisi‐NonCommercial‐NoDerivs License, which permits use and distribution in any
no modifications or adaptations are made.
by John Wiley & Sons, Ltd.
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childbirth, when progesterone levels decrease (Nappi et al., 2001;
Paoletti et al., 2006). Allopregnanolone is a neuroactive steroid that
has been shown in animal models to modulate neuronal excitability
through direct action on synaptic and extrasynaptic GABAA recep-
tors (Belelli et al., 2009; Lambert, Belelli, Harney, Peters, &
Frenguelli, 2001). It appears to play a significant role in affective
disturbances that occur with changes in reproductive endocrine
function, such as during the postpartum period (Amin et al., 2006;
Schiller, Meltzer‐Brody, & Rubinow, 2014a; Schiller, Schmidt, &
Rubinow, 2014b). Failure of GABAA receptors to adapt to abrupt
changes in allopregnanolone levels at parturition may play a part in
triggering PPD (Maguire & Mody, 2008). Allopregnanolone has
been implicated in preclinical models of anxiolysis and mood
improvement (Schiller et al., 2014b; Schule, Nothdurfter, &
Rupprecht, 2014), with evidence that elevated allopregnanolone
levels may protect against depressed mood during pregnancy
(Hellgren, Åkerud, Skalkidou, Bäckström, & Sundström‐Poromaa,
2014). Preclinical data suggest anxiogenic effects of low
allopregnanolone concentrations (Andréen et al., 2009). On the basis
of preclinical models, we hypothesize that the abrupt postpartum
decline in allopregnanolone may be associated with symptoms of
PPD. This supports the rationale for examining the effects of treat-
ment of PPD patients with therapeutic doses of allopregnanolone
equivalent to third trimester levels.
Although selective serotonin reuptake inhibitors (SSRIs) are
commonly used as first‐line PPD treatment, there is limited evidence
for their use in the postpartum period specifically, and the proportion
of PPD patients treated successfully with SSRIs has a wide range
(43%–88%; Austin, Middleton, Reilly, & Highet, 2013; De Crescenzo,
Perelli, Armando, & Vicari, 2014; Kim, Epperson, Weiss, & Wisner,
2014; Misri, Swift, Abizadeh, & Shankar, 2016). Considering the patho-
physiology of depression in the perinatal period and the negative conse-
quences of untreated PPD, development of efficacious new treatments
with more targeted mechanisms of action is warranted. Brexanolone
(USAN; formerly SAGE‐547 Injection), a proprietary, aqueous formula-
tion of allopregnanolone in sulfobutylether‐β‐cyclodextrin, was
evaluated in an open‐label, proof‐of‐concept study for treatment of
severe PPD, with the primary objective of evaluating safety and
tolerability. Secondary and exploratory objectives included assessment
of the effects of brexanolone on depression and anxiety symptoms.2 | METHODS
2.1 | Design and patients
This open‐label, proof‐of‐concept study enrolled healthy females
18–45 years old admitted to the University of North Carolina at
Chapel Hill Perinatal Psychiatry Inpatient Unit (PPIU) for a major
depressive episode beginning no earlier than the third trimester and
no later than 12 weeks following delivery. Admission to the PPIU
occurred 14 days to 20 weeks postpartum. At the screening visit, a
score of ≥20 on the 17‐item Hamilton Rating Scale for Depression
(HAMD; Hamilton, 1960) was required for inclusion. If patients weretaking antidepressants for longer than 2 weeks on a stable dose, they
were allowed to continue their medications during the brexanolone
dosing period. Two patients were taking sertraline (50 and 100 mg)
during brexanolone administration. Three of the women had prior
PPD episodes, and two also experienced prior major depressive epi-
sodes outside of the peripartum period. All women participated in
the standard PPIU program, which included psychotherapy and has
been previously described (Kimmel et al., 2016; Meltzer‐Brody et al.,
2014). Permanent weaning from breastfeeding prior to Visit 1 was
required. Written informed consent was obtained prior to screening,
and the study was approved by the UNC institutional review board.
The first patient was enrolled January 9, 2015; last patient follow‐up
was June 8, 2015.2.2 | Dosing and administration
Brexanolone dosing was chosen to target allopregnanolone exposure in
the third trimester (~150 nM, Luisi et al., 2000). Study timeline, dosing
schedule, and dosing regimen are presented in Figure 1 and Table 1.
After the first and second patient completed dosing andHour 84 assess-
ments, safety data were reviewed before enrolling the next patient.2.3 | Procedures
Prior to Day 1 dosing, vital signs, HAMD, Edinburgh Postnatal
Depression Scale (EPDS), Generalized Anxiety Disorder 7‐item Scale
(GAD‐7), Patient Health Questionnaire (PHQ‐9), Stanford Sleepiness
Scale, and Columbia–Suicide Severity Rating Scale were administered
(Cox, Holden, & Sagovsky, 1987; Hoddes, Zarcone, Smythe, Phillips,
& Dement, 1973; Kroenke, Spitzer, & Williams, 2001; Posner et al.,
2011; Spitzer, Kroenke, Williams, & Löwe, 2006). Clinical Global
Impression‐Improvement (CGI‐I) was first assessed at 12 hours
postinfusion initiation. All assessments were repeated at Hours 24,
36, 48, 60, and 84 (HAMD also at Hour 12). All evaluators received
HAMD training and were experienced in the evaluation of patients.
Adverse events (AEs) were monitored throughout treatment and
follow‐up. Blood samples for pharmacokinetic (PK) analysis were
obtained preinfusion and periodically through Hour 72 (Supplemen-
tal Methods).2.4 | Analysis
Descriptive statistics were calculated and summarized for all
endpoints. Baseline values were defined as the last value prior to
study drug infusion. Primary outcomes were safety and tolerability
measures, including treatment‐emergent AEs and changes from
baseline in physical and psychiatric evaluations. Secondary outcomes
were assessments of efficacy. The key efficacy measure was change
from baseline in HAMD total score. A paired t test was performed
to evaluate whether the change in HAMD from baseline to the
end of infusion (Hour 60) was nonzero. Exploratory endpoints
included EPDS, GAD‐7, PHQ‐9, and Stanford Sleepiness Scale scores
(Supplemental Methods).
FIGURE 1 Overview of trial design and dosing. Dosing began in the morning of Day 1 with a 12‐hour titration period in which brexanolone was
infused at 25%, 50%, then 75% of the maintenance dose for 4 hours at each level. Maintenance dosing began at Hour 12 and continued for
36 hours to achieve a target steady‐state plasma concentration of ~150 nM. At Hour 48, the dose was then tapered over the next 12 hours to 75%,
50%, and then 25% of the maintenance dose to allow physiologic adjustment to decreasing allopregnanolone levels. AE = adverse event;
SAE = serious adverse event
TABLE 1 Brexanolone dosing regimen
Study day (D) Hour Type and duration of Brexanolone infusion (h) Description
Titration infusion
D1 H1–H4 4 21.5 μg·kg−1·hr−1 (25% of the maintenance rate)
H5–H8 4 43 μg·kg−1·hr−1 (50% of the maintenance rate)
H9–H12 4 64.5 μg·kg−1·hr−1 (75% of the maintenance rate)
Maintenance infusion
D1–D3 H13–H48 36 86 μg·kg−1·hr−1
Taper infusions
D3 H49–H52 4 64.5 μg·kg−1·hr−1 (75% of the maintenance rate)
H53–H56 4 43 μg·kg−1·hr−1 (50% of the maintenance rate)
H57–H60 4 21.5 μg·kg·hr−1 (75% of the maintenance rate)
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3.1 | Patients
Four of six screened patients (age 27–42 years) met inclusion criteria,
enrolled, and completed the study. Based on the observed outcomes
in the four enrolled patients, the trial was stopped before reaching
the protocol criterion of 10 evaluable patients. Three enrolled patients
had a prior history of PPD, and three were taking concomitant psycho-
tropic medications. Mean HAMD total score at baseline was
26.5  4.1 (range 22–32), indicating severe depression (Zimmerman,
Martinez, Young, Chelminski, & Dalrymple, 2013). Preinfusion, three
patients reported nonspecific thoughts of suicide ideation (one
reported an actual suicide attempt during her lifetime).3.2 | Safety, PK, and efficacy
AEs were reported by all four patients (14 total; 10 considered treat-
ment related). Sedation was reported by two patients, and all other
events were reported by one patient each (infusion site discomfort,
infusion site erythema, infusion site pain, rash, thyroid stimulating hor-
mone increase, dizziness, flushing, and oropharyngeal pain). All AEs
were of mild or moderate severity and self‐limited. No serious AEswere reported. No patients were discontinued because of an AE. Three
patients had AE‐related dosage adjustments (Supplemental Results
and Table S1). There were no clinically important changes from base-
line in physical exam, electrocardiogram, laboratory parameters, or vital
signs. There were no reports of suicidal behaviour or ideation
postbaseline through Hour 84. PK data are summarized in Table S2
and Figure S1.
Mean HAMD, EPDS, GAD‐7, and PHQ‐9 scores decreased at the
first assessment after infusion initiation and remained low through
the end of infusion (Hour 60) and the last time point assessed (Hour 84;
Figure 2). Mean HAMD total score was 1.8  1.5 (p = .001 vs. baseline)
at Hour 60 and 5.3  2.9 at Hour 84 (81% decrease from baseline at
Hour 84). HAMD total scores for all patients were ≤7 at all assessments
from Hour 24 onward, indicating symptom remission (Zimmerman
et al., 2013; Figure S2). Mean CGI‐I score was 1.8  0.5 at first assess-
ment (Hour 12) and remained <2 at every subsequent assessment.4 | DISCUSSION
In this small proof‐of‐concept study, brexanolone appeared well toler-
ated in four patients with severe PPD. Three patients had precaution-
ary dosage adjustments due to mild or moderate AEs but completed
FIGURE 2 Mean total scores for efficacy assessments (N = 4). Mean change from baseline values for HAMD, EPDS, GAD‐7, and PHQ‐9 total
scores at each time point assessed. For HAMD, total score ≤ 7 was considered a measure of symptom remission. Planned assessment at end of
infusion (Hour 60) revealed a significant decrease versus baseline (p = .001). HAMD = Hamilton Rating Scale for Depression; EPDS = Edinburgh
Postnatal Depression Scale; GAD‐7 = Generalized Anxiety Disorder 7‐item Scale; PHQ‐9 = Patient Health Questionnaire
4 of 6 KANES ET AL.the trial, and no serious AEs were reported. Assessments of depression
(HAMD and EPDS) and anxiety (GAD‐7) demonstrated rapid symptom
reduction that was maintained through the last assessment.
This is the first evaluation of allopregnanolone as a PPD
treatment. Current standard of care for severe PPD often comprises
pharmacologic treatment in conjunction with psychotherapy and
other nonpharmacological interventions. Among pharmacological
approaches, SSRIs tend to be preferred despite varying response
rates (Austin et al., 2013; Kim et al., 2014; Misri et al., 2016), sug-
gesting a need for more targeted PPD therapies. In this study,
patients achieved rapid reduction of symptoms based on HAMD
and CGI‐I scores, with clinically relevant improvements from
baseline beginning at the first assessment post infusion initiation
(Hour 12) and continuing through Hour 84, an important finding
given that SSRIs can require more time to have a therapeutic effect
(De Crescenzo et al., 2014). Notably, because established psycho-
tropic medications were continued during the trial in 3 out of the
4 patients, we cannot exclude that this effect may not be only due
to brexanolone administration. An additional limitation is the lack
of external raters.
Because severe maternal PPD has far‐reaching impact on the
mother, infant, and family, we hypothesize that a pharmacotherapy
with potentially fewer AEs and greater efficacy due a targetedmechanism of action is desirable. Further, recent reviews of the
treatment of PPD with SSRI antidepressants have highlighted the lack
of data or small number of studies available for analysis (Molyneaux,
Howard, Mcgeown, Karia, & Trevillion, 2014), indicating a need for
further investigations and additional pharmacological PPD therapies.
The potential for brexanolone to be broadly applicable to depression
beyond PPD is unclear and has not been evaluated.5 | CONCLUSION
Though limitations include its open‐label design and relatively short
treatment and assessment period, this small exploratory study suggests
that brexanolone, and by extension positive allosteric GABAA receptor
modulation with neuroactive steroids, may be an important therapeutic
modality in PPD. The activity signal supports a role for allopregnanolone
in the pathophysiology of PPD and warranted early study discontinua-
tion in order to accelerate implementation of a larger placebo‐con-
trolled, double‐blind trial to validate and extend these findings.ACKNOWLEDGEMENTS
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